Therapeutic response in musculoskeletal soft tissue sarcomas: evaluation by MRI.

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.
NMR in Biomedicine (Impact Factor: 3.56). 07/2011; 24(6):750-63. DOI: 10.1002/nbm.1731
Source: PubMed

ABSTRACT This article provides a literature review of the use of MRI in monitoring the treatment response of soft tissue sarcomas. The basic classification and physiology of soft tissue tumors are introduced. Then, the major treatment options for soft tissue sarcomas are summarized with brief coverage of possible responses and grading systems. Four major branches of MRI techniques are covered, including conventional T(1) - and T(2) -weighted imaging, contrast-enhanced MRI, MR diffusion and perfusion imaging, and MRS, with a focus on the tumor microenvironment. Although this literature survey focuses on recent clinical developments using these MRI techniques, research venues in preclinical studies, as well as in potential applications other than soft tissue sarcomas, are also included when comparable and/or mutually supporting. Examples from other less-discussed MRI modalities are also briefly covered, not only to complement, but also to expand, the scope and depth of information for various kinds of lesions.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Magnetic resonance spectroscopy (MRS) is an imaging approach that allows for the noninvasive molecular characterization of a region of interest. By detecting signals of water, lipids, and other metabolites, MRS can provide metabolic information for lesion characterization and assessment of treatment response. Although MRS has been routinely used in the brain, clinical applications within the musculoskeletal system have only more recently emerged. The aim of this article is to review the technical considerations for performing MRS in the musculoskeletal system, focusing on proton MRS, and to discuss its potential roles in musculoskeletal tumor imaging and the assessment of muscle physiology and disease.
    Indian Journal of Radiology and Imaging 07/2014; 24(3):210-6.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To overcome each limitation of morphological and functional imaging procedures, hybrid imaging systems have been developed and introduced into clinical routine. It has been increasingly discussed whether magnetic resonance imaging (MRI) might be an appropriate alternative for computed tomography (CT). The major advantage of positron emission tomography (PET)/MR consists of combined metabolic and anatomical information in a single imaging session that provides superior soft tissue characterization of MRI over CT. Until now, fusion image has been effectively utilized in oncologic indications. Because biopsy cannot be replaced by images for definite diagnosis, fusion imaging may be more efficient for staging based on nodal spread or metastases rather than the diagnosis of primary tumor, and it can be proficient for treatment response or postoperative assessment. This review describes mainly oncologic and nontumorous conditions among the musculoskeletal applications of PET/MR.
    Seminars in Musculoskeletal Radiology 04/2014; 18(2):203-16. · 1.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PET/MRI is an evolving hybrid imaging modality which combines the inherent strengths of MRIs soft-tissue and contrast resolution and PETs functional metabolic capabilities. Bone and soft-tissue sarcoma are a relatively rare tumor entity, relying on MRI for local staging and often on PET/CT for lymph node involvement and metastatic spread evaluation. The purpose of this article is to demonstrate the successful use of PET/MRI in two sarcoma patients. We also use these patients as a starting point to discuss how PET/MRI might be of value in sarcoma. Among its potential benefits are: superior TNM staging than either modality alone, decreased radiation dose, more sensitive and specific follow-up and better assessment of treatment response. These potentials need to be investigated in future PET/MRI soft-tissue sarcoma trials.
    International Journal of Clinical and Experimental Medicine 01/2014; 7(3):640-8. · 1.42 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014